Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In the pharmacy business, the unit price of technical fees increased due to the acquisition of the add-on for establishing a medical DX promotion system and a higher usage rate of generic drugs, while prescription periods became longer and personnel expenses increased. In the BPO business, growth in demand for dispatched medical representatives, expansion of customers in the publishing-related business and in-house production contributed to results. In the pharmaceutical business, new products from Daiichi Sankyo Espha made a significant contribution.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥290,772 million (YoY +10.2%) |
| Operating profit | ¥14,811 million (YoY +10.0%) |
| Ordinary income | ¥14,879 million (YoY +7.6%) |
| Profit attributable to owners of the parent | ¥7,408 million (YoY +43.5%) |
| Net income per share | ¥197.35 |
| Operating Margin | Current fiscal year 5.1 ％ / Previous period 5.1 ％ |
| Equity ratio | End of the current fiscal period 36.3 ％ / End of previous period 35.8 ％ |
| Total assets | ¥158,116 million |
| Net assets | ¥59,840 million |
| Cash flows from operating activities | ¥18,665 million |
| Cash flows from investing activities | ¥-9,088 million |
| Cash flows from financing activities | ¥-14,966 million |
| Cash and cash equivalents at end of period | ¥20,988 million |
| Full-year earnings forecast | Net Sales ¥315,000 million (YoY +8.3%) / Operating profit ¥16,500 million (YoY +11.4%) / Ordinary income ¥16,500 million (YoY +10.9%) / Net income ¥7,800 million (YoY +5.3%) |
| Annual Dividend Forecast | ¥34 → ¥54 |
| Payout ratio | Current fiscal year 25.3 ％ / Next-year forecast 26 ％ |
| Segment revenue | Pharmacy business ¥177,461 million (YoY +3.4%), BPO Business ¥14,300 million (YoY +5.1%), Pharmaceutical Business ¥99,010 million (YoY +25.8%) |
| Segment profit | Pharmacy business ¥9,730 million (YoY -3.0%), BPO Business ¥1,898 million (YoY +11.3%), Pharmaceutical Business ¥6,960 million (YoY +32.0%) |
| Depreciation and amortization | ¥5,592 million |
| Impairment loss | ¥393 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥70 million, Other ¥6 million / Extraordinary loss Loss on Disposal of Fixed Assets ¥77 million, Loss on sale of fixed assets ¥42 million, Impairment Losses ¥393 million, Business restructuring loss ¥59 million, Other ¥1 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 38,902,785 Shares |
| Treasury Shares at Period-End | 1,325,219 Shares |
| Factors Behind Changes in Business Performance | In the pharmacy business, the unit price of technical fees increased due to the acquisition of the add-on for establishing a medical DX promotion system and a higher usage rate of generic drugs, while prescription periods became longer and personnel expenses increased. In the BPO business, growth in demand for dispatched medical representatives, expansion of customers in the publishing-related business and in-house production contributed to results. In the pharmaceutical business, new products from Daiichi Sankyo Espha made a significant contribution. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the pharmacy business, the unit price of technical fees increased due to the acquisition of the add-on for establishing a medical DX promotion system and a higher usage rate of generic drugs, while longer prescription periods and higher salaries resulted in increased personnel expenses. In the BPO business, growth in demand for dispatched medical representatives, expansion of customers in the publishing-related business and higher margins from in-house production contributed to results. In the pharmaceutical business, the launch of new products made a significant contribution to results.